bluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock.

BLUE has been the subject of a number of other reports. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Baird R W lowered bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. Wells Fargo & Company reduced their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th. Finally, Barclays reduced their price target on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, bluebird bio has a consensus rating of “Hold” and a consensus price target of $44.60.

bluebird bio Trading Down 1.7 %

BLUE stock opened at $4.12 on Tuesday. The company has a market cap of $40.33 million, a price-to-earnings ratio of -0.11 and a beta of 0.41. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The business has a fifty day simple moving average of $4.23 and a 200-day simple moving average of $6.82. bluebird bio has a 52 week low of $3.56 and a 52 week high of $28.60.

Hedge Funds Weigh In On bluebird bio

A number of institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp raised its position in shares of bluebird bio by 12.7% in the 1st quarter. Bank of New York Mellon Corp now owns 32,759 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 3,686 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new position in shares of bluebird bio in the 4th quarter valued at approximately $175,000. Barclays PLC raised its position in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares in the last quarter. Geode Capital Management LLC raised its position in shares of bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after acquiring an additional 43,382 shares during the last quarter. 87.43% of the stock is owned by institutional investors and hedge funds.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.